↑ 薬物リストへ　← 戻る

Triomar™ (omega-3 fatty acids)    (DrugBank: Omega-3 fatty acids, Omega-3)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎1

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00360906
(ClinicalTrials.gov)		December 20044/8/2006Omega-3 Fatty Acid Treatment in Multiple SclerosisOmega-3 Fatty Acid Treatment in Multiple SclerosisRelapsing-Remitting Multiple SclerosisDrug: Triomar™ (omega-3 fatty acids)Haukeland University HospitalThe Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham HealthCompleted18 Years55 YearsBoth100Phase 2;Phase 3Norway